105 related articles for article (PubMed ID: 34776348)
41. Lack of association between either outpatient or inpatient glycemic control and COVID-19 illness severity or mortality in patients with diabetes.
Mehta PB; Kohn MA; Koliwad SK; Rushakoff RJ
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 34059527
[TBL] [Abstract][Full Text] [Related]
42. RESULTS OF MEDICAL-SOCIAL RESEARCH ON MEDICAL CARE QUALITY FOR PATIENTS WITH COVID-19 OF INPATIENT HOSPITAL DEPARTMENTS IN SUMY REGION.
Dryha NO; Stepanenko AV; Rudenko LA; Zhaldak DO; Piven SM; Plakhtiienko IO
Wiad Lek; 2021; 74(5):1057-1060. PubMed ID: 34090263
[TBL] [Abstract][Full Text] [Related]
43. Characteristics, Management, and Case-Fatality of Patients Hospitalized for Stroke with a Diagnosis of COVID-19 in France.
Gabet A; Grave C; Chatignoux E; Tuppin P; Béjot Y; Olié V
Neuroepidemiology; 2021; 55(4):323-330. PubMed ID: 34167111
[TBL] [Abstract][Full Text] [Related]
44. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.
Shi S; Qin M; Shen B; Cai Y; Liu T; Yang F; Gong W; Liu X; Liang J; Zhao Q; Huang H; Yang B; Huang C
JAMA Cardiol; 2020 Jul; 5(7):802-810. PubMed ID: 32211816
[TBL] [Abstract][Full Text] [Related]
45. Differences in COVID-19 treatment across Japan: Analysis of the COVID-19 Registry Japan (COVIREGI-JP).
Asai Y; Ohashi T; Imai K; Murata K; Tsuzuki S; Matsunaga N; Ohmagari N
J Infect Chemother; 2024 Jan; 30(1):20-28. PubMed ID: 37689136
[TBL] [Abstract][Full Text] [Related]
46. Age distribution and disease severity of COVID-19 patients continued to change in a time-dependent manner from May 2021 to April 2022 in the regional core hospital in Japan.
Kawaura F; Kishi T; Yamamoto T; Nakayama S; Goto T; Tsurusawa R; Katagiri T; Yamanouchi K; Matsuo A; Kobayashi-Watanabe N; Imamura T; Hirooka Y; Takagi K; Umemura T; Fujimoto K; Hayashi S; Takamori A
Drug Discov Ther; 2023 Mar; 17(1):60-65. PubMed ID: 36843034
[TBL] [Abstract][Full Text] [Related]
47. Impact of regional heterogeneity on the severity of COVID-19.
Tsuzuki S; Asai Y; Matsunaga N; Ishioka H; Akiyama T; Ohmagari N
J Infect Chemother; 2022 Apr; 28(4):554-557. PubMed ID: 35034854
[TBL] [Abstract][Full Text] [Related]
48. Survival Analysis and Contributing Factors among PCR-Confirmed Adult Inpatients during the Endemic Phase of COVID-19.
Benites-Godínez V; Mendoza-Cano O; Trujillo X; Ríos-Silva M; Lugo-Radillo A; Bricio-Barrios JA; Cuevas-Arellano HB; Ríos-Bracamontes EF; Serrano-Moreno W; Cárdenas Y; Baltazar-Rodríguez GM; Ortega-Ramírez AD; Murillo-Zamora E
Diseases; 2023 Sep; 11(3):. PubMed ID: 37754315
[TBL] [Abstract][Full Text] [Related]
49. Glomerular Diseases with Reference to COVID-19.
Gulati S; Prasad N; Sahay M; Kute V; Agarwal SK;
Indian J Nephrol; 2020; 30(3):158-160. PubMed ID: 33013061
[TBL] [Abstract][Full Text] [Related]
50. A surveillance study of SARS-CoV-2 infection in immunosuppressed patients.
Bradshaw D; Harrison K; Page E; Taha Y; Killip M; Parkes S; Lloyd C; Kokocinska M; Davies K; Beetar-King T; Zambon M; Kelly D
J Infect Prev; 2024 Mar; 25(1-2):38-40. PubMed ID: 38362110
[No Abstract] [Full Text] [Related]
51. Excess Mortality in COVID-19-Positive Versus COVID-19-Negative Inpatients With Diabetes: A Nationwide Study.
Spanakis EK; Yoo A; Ajayi ON; Siddiqui T; Khan MM; Seliger SL; Klonoff DC; Feng Z; Sorkin JD
Diabetes Care; 2021 Sep; 44(9):e169-e170. PubMed ID: 34233926
[No Abstract] [Full Text] [Related]
52. Experts Discuss COVID-19-Variants and Vaccine Efficacy, Immunosuppressed Patients, and More.
JAMA; 2021 Apr; ():. PubMed ID: 33851954
[No Abstract] [Full Text] [Related]
53. Correction to: "Living with COVID"-implications for immunosuppressed and immunocompromised.
Nune A; Iyengar KP; Botchu R; Barman B; Manzo C
Clin Rheumatol; 2022 Nov; 41(11):3595. PubMed ID: 36001246
[No Abstract] [Full Text] [Related]
54. Correction to: Prognostic factors for COVID-19 infected inpatients with chronic diseases.
QJM; 2023 Oct; 116(10):889. PubMed ID: 37804106
[No Abstract] [Full Text] [Related]
55. Response to: Prognostic factors for COVID-19 infected inpatients with chronic diseases.
Mukherjee A; Kumar G; Panda S
QJM; 2023 Oct; 116(10):887-888. PubMed ID: 37335860
[No Abstract] [Full Text] [Related]
56. Prognostic factors for COVID-19 infected inpatients with chronic diseases.
Lee YT; Wang PH; Chen CC; Chen SC
QJM; 2023 Oct; 116(10):886. PubMed ID: 37335852
[No Abstract] [Full Text] [Related]
57. Survival analysis of all critically ill patients with COVID-19 admitted to the main hospital in Mogadishu, Somalia, 30 March-12 June 2020: which interventions are proving effective in fragile states?
Ali MM; Malik MR; Ahmed AY; Bashir AM; Mohamed A; Abdi A; Obtel M
Int J Infect Dis; 2022 Jan; 114():202-209. PubMed ID: 34781004
[TBL] [Abstract][Full Text] [Related]
58. Clinical features and cognitive sequelae in COVID-19: a retrospective study on N=152 patients.
Manera MR; Fiabane E; Pain D; Aiello EN; Radici A; Ottonello M; Padovani M; Wilson BA; Fish J; Pistarini C
Neurol Sci; 2022 Jan; 43(1):45-50. PubMed ID: 34779965
[TBL] [Abstract][Full Text] [Related]
59. MIMIC-IV, a freely accessible electronic health record dataset.
Johnson AEW; Bulgarelli L; Shen L; Gayles A; Shammout A; Horng S; Pollard TJ; Hao S; Moody B; Gow B; Lehman LH; Celi LA; Mark RG
Sci Data; 2023 Jan; 10(1):1. PubMed ID: 36596836
[TBL] [Abstract][Full Text] [Related]
60. Smoking and severe illness in hospitalized COVID-19 patients in Japan.
Matsushita Y; Yokoyama T; Hayakawa K; Matsunaga N; Ohtsu H; Saito S; Terada M; Suzuki S; Morioka S; Kutsuna S; Mizoue T; Hara H; Kimura A; Ohmagari N
Int J Epidemiol; 2022 Aug; 51(4):1078-1087. PubMed ID: 34894230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
